Enfortumab vedotin-ejfv
Restricted to oncology in the outpatient setting. Insurance certification or PAP eligibility review required with each case before use. May be administered as "patient own medication" through PAP.
Miscellaneous Programs
Anti-Neoplastic Formulary
Reviewed: July 2020
High Value Care Committee: May 2021 - Approved
Restricted to oncology in the outpatient setting. Insurance certification or PAP eligibility review required with each case before use. May be administered as "patient own medication" through PAP.
Miscellaneous Programs
Anti-Neoplastic Formulary
Reviewed: July 2020
High Value Care Committee: May 2021 - Approved